Powered by

Regeneron Announces Positive Topline Phase 2 Data with Anti-C5 Antibody Pozelimab in Patients with a Rare Blood Disorder

Dec 05, 2019 - PR Newswire
Product Launch

PR Newswire

Results from initial 6-patient cohort show pozelimab reduced lactate dehydrogenase (LDH) to normal levels at week 8 in patients with paroxysmal nocturnal hemoglobinuria (PNH), utilizing a weekly subcutaneous dosing regimen

Second part of Phase 2 trial initiated; plans for Phase 3 program underway

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced topline data from the pozelimab (REGN3918) Phase 2 clinical program in paroxysmal nocturnal hemoglobinuria ...